Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 645-652

  Li, Qingdi ^a   Yu, Jing Jie ^a   Mu, Chuanjie ^a   Yunmbam, Manasses K ^a   Slavsky, Daniel ^a   Cross, Cheryl L ^a   Bostick Bruton, Frieda ^a   Reed, Eddie ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cisplatin; ERCC 1; Nucleotide excision repair; Ovarian cancer; Platinum DNA adduct

Indexed keywords

CISPLATIN; DNA; MESSENGER RNA;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL LINE; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; EXCISION REPAIR; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; WESTERN BLOTTING;

CELL NUCLEUS; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; OVARIAN NEOPLASMS; PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034054137     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treatment Reviews 24: 331-344, 1998.
2. Reed E: Ovarian cancer: molecular abnormalities. In: Bertino JR, ed. The Encyclopedia of Cancer. San Diego, CA: Academic Press, Inc., 1192-1200, 1996.
3. Reed E: The chemotherapy of ovarian cancer. PPO Updates 10: 1-12, 1996.
4. Reed E, Dabholkar M, Chabner BA: Platinum analogues. In: Chabner BA, Longo DL, ed. Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers 357-378, 1996.
5. Reed E: Platinum analogs, anticancer drugs. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott 390-400, 1993.
6. Reed E, Dabholkar M, Chabner BA: Platinum analogues. In: Chabner BA, Longo DL, ed. Cancer Chemotherapy. Philadelphia, PA: Lippincott-Raven Publishers 357-378, 1996.
7. Young RC, Perez CA, Hoskins WJ.: Cancer of the ovary. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer-Principles & Practice of Oncology. 4th ed. Philadelphia, PA: J.B. Lippincott 1245-1252, 1993.
8. Pil P, Lippard SJ: Cisplatin and related drugs. In: Bertino JR, ed. Encyclopedia of Cancer. San Diego, CA: Academic Press 392-410, 1997.
9. Lepre CA, Lippard SJ: Interaction of platinum antitumor compounds with DNA. Nucleic Acids Mol Biol 4: 9-38, 1990.
10. Mello JA, Trimmer EE, Kartalou M, Essigmann JM: Conflicting roles of mismatch and nucleotide excision repair in cellular susceptibility to anticancer drugs. Nucleic Acids Mol Biol 12: 249-274, 1998.
11. Reed E: Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 27: 187-201, 1998.
12. Gosland M. Lum B, Schimmelpfennig J, Baker J, Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39, 1996.
13. Dabholkar M, Reed E: Cisplatin, Cancer Chemother Biol Response Modif 16: 88-110, 1996.
14. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC: Increased DNA repair as a mechanism of acquired resistance to cisdiamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48: 5713-5716, 1988.
15. Parker RJ, Eastman A, Bostick-Bruton F, Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 773-777, 1991.
16. Chen G, Hutter KJ, Zeller WJ: Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 11: 273-281, 1995.
17. Godwin A, Meister A, O'Dwyer P, Huang C, Hamilton T, Anderson M: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
18. Kashani-Sabet M, Wang W, Scanlon KJ: Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265: 11285-11288, 1990.
19. Calsou P, Barret JM, Cros S, Salles B: DNA excision repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur J Biochem 211: 403-409, 1993.
20. Hill BT, Scanlon KJ, Hansson J: Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30: 832-837, 1994.
21. Pooter CMD, Oosterom ATV, Scalliet PG, Maes RA, Brujin EAD: Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. Biochem Pharmacol 51: 629-634, 1996.
22. Lee KB, Parker RJ, Bohr VA, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14: 2177-2180, 1993.
23. Zhen W, Link CJ, O'Connor PM, Reed E, Parker RJ, Bohr VA: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698, 1992.
24. Jones JC, Zhen W, Reed E, Parker RJ, Sancar A, Bohr VA: Preferential DNA repair of cisplatinum lesions in active genes in CHO cells. J Biol Chem 266: 7101-7107, 1991.
25. Moggs JG, Yarema KJ, Essigmann JM, Wood RD: Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem 271: 7177-7186, 1996.
26. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ: Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35: 10004-10013, 1996.
27. Suncar A, Tang MS: Nucleotide excision repair. Photochem Photobiol 57: 905-921, 1993.
28. Sancar A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
29. Sancar A: Excision repair in mammalian cells. J Biol Chem 270: 15915-15918, 1995.
30. Sancar A: DNA excision repair. Annu Rev Biochem 65: 43-81, 1996.
31. Petit C, Sancar A. Nucleotide excision repair: From E. coli to man. Biochimic 81: 15-25, 1999.
32. Wood RD: DNA repair in eukaryotes. Annu Rev Biochem 65: 135-167, 1996.
33. Aboussekhra A: Nucleotide excision repair in vitro and in normal/abnormal human cells. Cell Pharmacol 3: 221-224, 1996.
34. Friedberg EC, Walker GC, Siede W: DNA Repair and Mutagenesis. Washington, D.C.: ASM Press, 1995.
35. van Duin M, de Wit J, Hoeijmakers JHJ, Bootsma D: Molecular cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 44: 913-923, 1986.
36. Sijbers AM, deLaat WL, Wei YF, Moggs JG, Hoeijmakers JHJ, Wood RD: Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 86: 811-822, 1996.
37. Westerveld A, Hoeijmakers JHJ, van Duin M, de Wit J, Wood RD, Bootsma D: Molecular cloning of a human DNA repair gene. Nature 310: 425-429, 1984.
38. Melton DW, Ketchen AM. Squires S, Johnson R: Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 111: 395-404, 1998.
39. McWhir J, Selfridge J, Harrison DJ: Mice with DNA repair gene (ERCC1) deficiency have elvated levels of p53, liver nuclear abnormalities and die before weaning. Nature Genet 4: 217-223, 1993.
40. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517, 1992.
41. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPA and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
42. Yu JJ, Dabholkar M, Bennett WP, Welsh JA, Mu C, Bostick-Bruton F, Reed E: Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Int J Oncol 8: 313-317, 1996.
43. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425, 1998.
44. Li Q, Bostick-Bruton F, Reed E: Effect of interleukin-1α and tumor necrosis factor-a on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. Anticancer Res 18: 2283-2288, 1998.
45. Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick-Bruton F, Reed E: Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian tumor cells. Int J Oncol 13: 987-992, 1998.
46. Li Q, Tsang B, Bostick-Bruton F, Reed E: Modulation of ERCC-1 messenger RNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 57: 347-353, 1999.
47. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF: Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418, 1987.
48. Chomezynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
49. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A laboratory Manual.Cold Spring Harbor, NY: Cold Spring Harbor, 1989.
50. Yu JJ, Mu C, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E: Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Int J Mol Med 1: 617-620, 1998.
51. Towbin H, Staehelin T, Gordon J: Electrophoretic trnasfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
52. Raj NBK, Pitha PM:ΠTwo levels of regulation of beta-interferon gene expression in human cells. Proc. Natl. Acad. Sci. USA 80: 3923-3927, 1983.
53. Flamm WG, Birnstiel ML, Walker PMB. Preparation and fractionation, and isolation of single strands of DNA by isopycnic ultracentrifugation in fixed-angle rotors. In: Birnie G, Fox SM, ed. Subcellular Components, Preparation and Fractionation. London: Butterworth and Co., Ltd., 125-155, 1969.
54. Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E: Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absoption spectrometry. Carcinogenesis 12: 1253-1258, 1991.
55. Walker GC: Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli. Microbiol Rev 48: 60-93, 1984.
56. Walker GC: Inducible DNA repair systems. Annu Rev Biochem 54: 425-457, 1985.
57. Kirkpatrick DT: Roles of the DNA mismatch repair and nucleotide excision repair proteins during meiosis. Cell Mol Life Sci 55: 437-449, 1999.
58. Wood RD: Nucleotide excision repair in mammalian cells. J Biol Chem 272: 23465-23468, 1997.
59. Vermeulen W, deBoer J, deLaat WL, Bootsma D, Hoeijmakers JHJ: Mammalian nucleotide excision repair and syndromes. Biochem Soc Trans 25: 309-315, 1997.
60. Metzger R, Leichman CG, Danenherg KD, Danenberg PV, Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
61. Benchekroun MN, Parker RJ, Reed E, Sinha BK: Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1α. Biochem Biophys Res Commun 195: 294-300, 1993.
62. Benchekroun MN, Parker RJ, Dabholkar M, Reed E, Sinha BK. Effects of interleukin-1α on DNA repair in human ovarian carcinoma (NIH: OVCAR-3) cells: Implications in the mechanism of sensitization of cis-diamminedichloroplatinum (II). Mol Pharmacol 47: 1255-1260, 1995.
63. Wang Z, Lee KB, Reed E, Sinha BK: Sensitization by interleukin-1α of carboplatinum anti-tumor activity against human ovarian (NIH: OVCAR-3) carcinoma cells in vitro and in vivo. Int J Cancer 67: 583-587, 1996.
64. Li Q, Zhang L, Tsang B, Gardner K, Bostick-Bruton F, Reed E: Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells. Cell Mol Life Sci 55: 456-466, 1999.
65. Zhai X, Beckmann H, Jantzen HM, Essigmann JM: Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37: 16307-16315, 1998.
66. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E: A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutation Res Genomics 382: 13-20, 1997.
67. Lathe R: Synthetic oligonucleotide probes deduced from amino acid sequence data: Theoretical and pratical considerations. J Mol Biol 183: 1-12, 1985.
68. Hatfield DL, Jung JE, Lee BJ, Choi IS: Aminoacyl-tRNA (anti-codon): codon adaptation in higher eukaryotes. In: Hatfield DL, Lee BJ, Pirtle RM, ed. Transfer RNA in protein synthesis. Boca Raton, FL: CRC Press 113-123, 1992.
69. Hatfield GW, Gutman GA: Codon pair utilization bias in bacteria, yeast, and mammals. In: Hatfield DL, Lee BJ, Pirtle RM, ed. Transfer RNA in protein synthesis. Boca Raton, FL: CRC Press, 157-189, 1992.
70. Li L, Liu X, Glosman AB, Keating MJ, Stros M, Plunkett W, Young LY: Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 57: 1487-1494, 1997.